MercachemSyncom is the leading European mid-sized contract research organization that offers innovative best-in-class chemistry solutions. This is delivered by more than 300 employees and operations in Nijmegen and Groningen, the Netherlands, and Prague, Czech Republic.

We provide tailor-made synthetic solutions for the design and synthesis of small-molecule hits to the delivery of first GMP batches of identified clinical candidates. Our molecular inventiveness is based on our firm understanding and extensive knowledge base of organic chemistry. We blend knowledge of hard science with creativity to make great leaps forward to create new connections between previously unrelated molecules.

At MercachemSyncom, we cherish the diversity of opinions that come from all levels in our organization. This provides a constant stream of creative ideas that are translated into pragmatic solutions for your projects. We maintain a personal touch with the resources to support the scale of projects.



MercachemSyncom is the result of merging two industry-leading companies: Syncom and Mercachem. Together, MercachemSyncom is an integrated provider of chemistry solutions for a wide range of industries, specializing in all stages of drug discovery.

We take pride in our ability to meet all of a company’s needs, to adapt to changing requirements, and to become a long-term partner. We believe that real impact is created through positive relationships, strong success records, and solid problem-solving abilities.



Eelco Ebbers is a co-founder of Mercachem B.V. Since 2013, he has been a member of the board at Novio Tech Campus, Nijmegen, and a member of the advisory board of the Institute of Applied Science in HAN University in Nijmegen.

Eelco obtained his MSc in 1992 and received his PhD in Organic Chemistry in 1997 from the Radboud University Nijmegen, The Netherlands.

Robert Hof worked at DSM and Pepscan Therapeutics, and since 2010 has been Chief Operating Officer at Syncom. With over 20 years of experience, he has held managerial positions in process R&D, cGMP manufacturing, and innovation management.

Robert received his MSc in 1990 and PhD in organic chemistry in 1995 from the University of Groningen, The Netherlands.

Frank Leemhuis, co-founder of Mercachem B.V., began his career in 1993 at Specs and Biospecs B.V. In 2010, he was named “Entrepreneur of the Year” by the City of Nijmegen. Since 2012, he has been a member of Board of Directors of Top Institute Pharma (now Lygature) in The Netherlands. He is also on the advisory board of the EFMC.

Frank received his MSc in 1988 and PhD in 1993, on the total syntheses of macrocyclic ring lactones.

Ton Vries has been Syncom’s CEO since 2000, when he succeeded Prof. Hans Wynberg, founder of Syncom. He has been involved in many different aspects of Syncom business, including scientific development, chiral technologies, business development, and business strategy.

Ton obtained his MSc in 1988 and received his PhD in Organic Chemistry in the field of chiral resolution in 1996 from the University of Groningen, The Netherlands.

Guillaume Jetten has been working in the healthcare industry for most of his career. He held positions at Merck, Sharpe & Dohme, and served as Chief Financial Officer (CFO) of Wolters Kluwer Health. He worked as CFO for Galapagos between 2009 and 2014.

Guillaume holds a master’s degree in economics from the University of Maastricht and is a Certified Registered Accountant.